As most specimens with PD-L1 levels of 1–4% had the highest CD8+ T-cells activity, it can be concluded that patients with a tumorigenic tumour have a survival advantage compared to patients with a tumour-suppressive tumour microenvironment and immune cell infiltrate. This evidence concerns the gene CD8A and neoplasm.